Henlius CEO Dr. Jason Zhu to Speak at the 2026 J.P. Morgan Healthcare Conference

The prestigious J.P. Morgan Healthcare Conference is set to take place from January 12 to 15, 2026, in San Francisco, where Dr. Jason Zhu, the Executive Director and Chief Executive Officer of Henlius, will be a keynote speaker on January 15. This conference is hailed as one of the most significant gatherings in the healthcare investment sector, drawing in industry leaders, innovators, and investors to discuss the latest advancements in pharmaceuticals and healthcare.

A Platform for Innovation

As one of the most anticipated events in the healthcare calendar, the J.P. Morgan Healthcare Conference offers a unique platform for companies to showcase their latest innovations and for investors to find promising opportunities. With over 8,000 participants expected, Dr. Zhu’s presentation will highlight Henlius' core strengths developed through its international expansion journey.

During his address, Dr. Zhu will also update attendees on Henlius' innovative product pipeline, which includes next-generation technology such as antibody-drug conjugates (ADCs) and multispecific T-cell engagers (TCEs). His insights on the company's strategic direction over the next five years are expected to shed light on how Henlius plans to solidify its position as a global biopharmaceutical leader.

Henlius: A Global Biopharmaceutical Leader

Founded in 2010, Henlius has transitioned from a startup to a robust biopharmaceutical company with a comprehensive integrated platform. The company has made significant strides by establishing dedicated clinical development, operations, and regulatory teams in vital markets such as the U.S. and Japan. This enables Henlius to conduct independent clinical trial engagements and streamline its interaction with global regulatory authorities, thereby facilitating faster access to markets.

Henlius’ commercial manufacturing facilities have secured GMP certifications in China, the European Union, and the United States. This broadens its capability to meet the growing demand for its products in more than 50 countries across six continents.

Commitment to Patient-Centric Solutions

Looking forward, Henlius remains committed to addressing unmet patient needs around the globe. By forging strategic alliances with global capital markets and industry partners, the company aims to enhance its innovation capacity and operational efficiency. This initiative is part of Henlius' vision to deliver high-quality, affordable biological medicines to patients worldwide.

The company has actively explored a comprehensive product pipeline that includes around 50 molecules and is advancing immuno-oncology combination therapies, particularly those involving its proprietary anti-PD-1 monoclonal antibody, HANSIZHUANG. This focus on innovation reflects Henlius’ commitment to improving patient outcomes in oncology and other areas.

A Look at the Product Portfolio

Some of their products such as HANSIZHUANG (serplulimab), which is the world’s first anti-PD-1 mAb for first-line treatment of small cell lung cancer, and the biosimilar medications like HANQUYOU (trastuzumab) and HANLIKANG (rituximab) have gained significant traction in multiple international markets, contributing to the company’s growing reputation in the biotech sector.

As Dr. Zhu prepares to take the stage at the J.P. Morgan Healthcare Conference, all eyes will be on Henlius as it showcases its achievements and vision for the future. The company’s ongoing commitment to innovation promises to make a substantial impact on the global healthcare landscape.

To learn more about Henlius and its innovative solutions in biopharmaceuticals, visit their official website and follow them on LinkedIn.